人骨髓瘤细胞MM1S
BLUEFBIO™ Product Sheet
|
细胞名称 |
人骨髓瘤细胞MM1.S |
|
|
|
货物编码 |
BFN60808555 |
||
|
产品规格 |
T25培养瓶x1 |
1.5ml冻存管x2 |
|
|
细胞数量 |
1x10^6 |
1x10^6 |
|
|
保存温度 |
37℃ |
-198℃ |
|
|
运输方式 |
常温保温运输 |
干冰运输 |
|
|
安全等级 |
1 |
||
|
用途限制 |
仅供科研 2类 |
||
|
培养体系 |
DMEM高糖+10%FBS+1%三抗 |
||
|
培养温度 |
37℃ |
二氧化碳浓度 |
5% |
|
简介 |
人骨髓瘤细胞MM1.S取自45岁女性供体外周血。该细胞源于ATCC |
||
|
注释 |
Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Part of: MD Anderson Cell Lines Project. Characteristics: Produces IgA lambda. Characteristics: Sensitive to dexamethasone. Doubling time: 80 hours (PubMed=25984343). Microsatellite instability: Instable (MSI-low) (Sanger). Omics: Array-based CGH. Omics: Deep exome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Derived from sampling site: Peripheral blood. |
||
|
基因突变 |
Heterozygous for KRAS p.Gly12Ala (c.35G>C) (PubMed=21173094; CCLE; Cosmic-CLP). Homozygous for TRAF3 p.Val536_Asn545delValPheValAlaGlnThrValLeuGluAsninsAsp (c.1604-1630delTCTTTGTGGCCCAAACTGTTCTAGAAA) (PubMed=17692805). |
||
|
HLA信息 |
/ |
||
|
STR信息 |
Amelogenin X CSF1PO 9,14 D3S1358 16,17 D5S818 8,12 D7S820 10,11 D8S1179 14 D13S317 13 D16S539 12 D18S51 11,16 D21S11 29,30 FGA 20,24 Penta D 2.2,9 Penta E 13,15 TH01 7,8 TPOX 8 vWA 15,17 |
||
|
参考文献 |
PubMed=30285677; DOI=10.1186/s12885-018-4840-5 Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P. Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines. BMC Cancer 18:940-940(2018)
PubMed=30545397; DOI=10.1186/s13045-018-0679-0 Tessoulin B., Moreau-Aubry A., Descamps G., Gomez-Bougie P., Maiga S., Gaignard A., Chiron D., Menoret E., Le Gouill S., Moreau P., Amiot M., Pellat-Deceunynck C. Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways. J. Hematol. Oncol. 11:137-137(2018)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019)
|
||
